Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. Heath on the Toxicity Profiles of Oral Antiandrogens in Nonmetastatic CRPC

January 3rd 2020

Elisabeth I. Heath, MD, FACP, discusses the safety profiles of apalutamide, enzalutamide, and darolutamide in nonmetastatic castration-resistant prostate cancer.

Darolutamide Takes Root With New Prostate Cancer Benchmark

December 19th 2019

Matthew R. Smith, MD, PhD, discusses key facets of darolutamide (Nubeqa) therapy in the treatment of patients with nonmetastatic prostate cancer.

Novel AR-Directed Agents Transform Nonmetastatic CRPC Paradigm

December 18th 2019

Elisabeth I. Heath, MD, FACP, discusses 3 pivotal trials and how they have impacted clinical practice in nonmetastatic castration-resistant prostate cancer.

FDA Approves Enzalutamide for Metastatic Castration-Sensitive Prostate Cancer

December 17th 2019

The FDA has approved a supplemental new drug application for enzalutamide (Xtandi) for the treatment of patients with metastatic castration-sensitive prostate cancer.

PARP Inhibitors Gain a Foothold in Prostate Cancer

December 12th 2019

Until strong findings emerged from the phase III PROfound study of PARP inhibitor olaparib (Lynparza) in patients with metastatic castration-resistant prostate cancer, targeted therapy had an uncertain foothold in this tumor type.

Dr. Moses on Recent Trials in mHSPC

December 7th 2019

Kelvin Alexander Moses, MD, PhD, discusses recent trials in metastatic hormone-sensitive prostate cancer.

Dr. Oh on Remaining Challenges in mHSPC

December 7th 2019

William K. Oh, MD, discusses remaining challenges in metastatic hormone-sensitive prostate cancer.

Patient Factors Critical to Treatment Selection in Prostate Cancer, RCC

December 5th 2019

Kelvin Alexander Moses, MD, PhD, discusses relevant data and treatment decisions in metastatic hormone-sensitive prostate cancer, as well as the role of cytoreductive nephrectomy in RCC. 

Germline Variants Provide Insight Into Tumor Growth in Prostate Cancer

December 5th 2019

Select DNA variants leading to methylation dysregulation within the germline DNA of men with localized prostate cancer were found to be predictive of disease biology, suggesting the prognostic capacity of inherited elements of a patient’s genome, according to data published in Nature Medicine.

Prostate Cancer Treatment Options Expand With ADT Combinations

December 4th 2019

David F. Penson, MD, MPH, MMHC, discusses the current armamentarium and ongoing research in prostate cancer.

Dr. Barocas on the CEASAR Trial in Localized Prostate Cancer

December 4th 2019

Daniel A. Barocas, MD, MPH, FACS, an associate professor in the Department of Urology at Vanderbilt University Medical Center, discusses the Comparative Effectiveness Analysis of Surgery and Radiation (CEASAR) trial in localized prostate cancer.

Population-Based Study Informs Decision-Making in Localized Prostate Cancer

December 2nd 2019

Daniel A. Barocas, MD, MPH, FACS, discusses the CEASAR study in prostate cancer, as well as therapeutic updates in renal cell carcinoma.

Enzalutamide Gains Approval in China for mCRPC

November 28th 2019

China’s National Medical Products Administration has granted approval to enzalutamide for the treatment of patients with metastatic castration-resistant prostate cancer who are asymptomatic or mildly symptomatic following progression on androgen deprivation therapy in whom chemotherapy is not yet clinically indicated.

Dr. Morris on Safety Profiles of AR Inhibitors in Prostate Cancer

November 27th 2019

David Morris, MD, FACS, discusses the safety profiles and common adverse events related to the androgen receptor inhibitors apalutamide, enzalutamide, and darolutamide for prostate cancer.

Expert Shares Insight on Recent Prostate Cancer Developments

November 27th 2019

Sam S. Chang, MD, discusses the utility of genetic testing in prostate cancer and pivotal research efforts.

Dr. Penson on Treatment Selection in Metastatic Hormone-Sensitive Prostate Cancer

November 22nd 2019

David F. Penson, MD, MPH, MMHC, discusses treatment selection in patients with metastatic hormone-sensitive prostate cancer.

Dr. Koo on New Management Strategies for Prostate Cancer

November 21st 2019

Phillip J. Koo, MD, discusses new management strategies for patients with prostate cancer.

Dr. Bryce on Potential Biomarkers of Response to Immunotherapy in Prostate Cancer

November 20th 2019

Alan H. Bryce, MD, discusses potential biomarkers of response to immunotherapy in prostate cancer.

Dr. Chang on the Use of PARP Inhibitors in Prostate Cancer

November 20th 2019

Sam S. Chang, MD, MBA, discusses the shift toward personalized therapy in prostate cancer.

Relugolix Elicits High Response Rate in Advanced Prostate Cancer

November 19th 2019

Treatment with relugolix achieved a high rate of sustained testosterone suppression to castrate levels in patients with androgen-sensitive advanced prostate cancer, meeting the primary endpoint of the phase III HERO trial.